The version of the article, “Low Levels of Low-Density Lipoprotein-C Associated With Proprotein Convertase Subtilisin Kexin 9 Inhibition Do Not Increase the Risk of Hemorrhagic Transformation” by Tran-Dinh et al that published online ahead-of-print on August 14, 2014, contained an error in Figures 1 and 2 legends. They have been corrected as follows:
Figure 1. Hemorrhagic transformation (HT) at 24 hours after cerebral ischemia/reperfusion in PCSK9−/− (n=14) and PCSK9+/+ (n=13) mice. A, Hemoglobin concentration (ng/mg protein) in ischemic cerebral tissue. PCSK9−/− (n=12) and PCSK9+/+ (n=13). B, Infarct volume (cm3). PCSK9−/− (n=14) and PCSK9+/+ (n=13). C, Representative TTC staining showing the infarct area (white) and HT (red hematomas and petechiae, arrows). PCSK9 indicates proprotein convertase subtilisin kexin 9.
Figure 2. Plasma lipids of PCSK9−/− and PCSK9+/+ mice after a high fat/high cholesterol diet. A, Low-density lipoprotein-cholesterol (LDLC) levels in plasma (g/L). B, LDL-C, high-density lipoprotein, and total cholesterol levels in plasma (g/L). Results are medians [min–max] and P values. HDL-C indicates high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; PCSK9 indicates proprotein convertase subtilisin kexin 9; TC, total cholesterol; and TTC, triphenyltetrazolium chloride.
This correction has been made to the online and print version of the article, which is available at http://stroke.ahajournals.org/content/45/10/3086.
- © 2014 American Heart Association, Inc.